

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **PROPOSAL FOR RESOLUTION ON AUTHORIZATION REGARDING NEW ISSUES**

The board of Alligator Bioscience AB (publ), Reg. No. 556597-8201, proposes that the annual shareholders' meeting on 9 May 2019 resolves to authorize the board, up until the next annual shareholders' meeting, at one or several occasions, with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares.

The reason for why a deviation from the shareholders' preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances.

The total number of shares that may be issued shall not exceed 17,847,000 shares, which corresponds to a dilution of approximately 20 percent calculated on the current number of shares.

In case the authorization is used for a new issue with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

The Chairman of the board, or anyone appointed by him, shall be authorized to make the minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (*Sw. Bolagsverket*).

### **Majority requirement**

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the annual shareholders' meeting.

---

Lund in April 2019

The board of directors for Alligator Bioscience AB (publ)